Publications by authors named "Mary Kate Hart"

Claim this Profile
R
Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice.
Axel T Lehrer, Teri-Ann S Wong, Michael M Lieberman, Tom Humphreys, David E Clements, Mary Kate Hart

Vaccine· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a Cynomolgus Macaque Model of Pneumonic Plague for Evaluation of Vaccine Efficacy.
Patricia Fellows, Jessica Price, Shannon Martin, Karen Metcalfe, Robert Krile, Mary Kate Hart

Clin Vaccine Immunol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.
Gerald Aichinger, Barbara Grohmann-Izay, Maikel V W van der Velden, Sandor Fritsch, Manuela Koska, Mary Kate Hart

Clin Vaccine Immunol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.
Douglas S Reed, Pamela J Glass, Russell R Bakken, James F Barth, Cathleen M Lind, Mary Kate Hart

J Virol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.
Andrew S Herbert, Ana I Kuehne, James F Barth, Ramon A Ortiz, Donald K Nichols, Mary Kate Hart

J Virol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designing and testing broadly-protective filoviral vaccines optimized for cytotoxic T-lymphocyte epitope coverage.
Paul W Fenimore, Majidat A Muhammad, William M Fischer, Brian T Foley, Russell R Bakken, Mary Kate Hart

PLoS One· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical development of a Vero cell culture-derived seasonal influenza vaccine.
Hartmut J Ehrlich, Gregory Berezuk, Sandor Fritsch, Gerald Aichinger, Julia Singer, Mary Kate Hart

Vaccine· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals.
Hartmut J Ehrlich, Julia Singer, Gregory Berezuk, Sandor Fritsch, Gerald Aichinger, Mary Kate Hart

Clin Infect Dis· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges.
Mary Kate Hart, George A Saviolakis, Susan L Welkos, Robert V House

Adv Prev Med· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial.
P Noel Barrett, Gregory Berezuk, Sandor Fritsch, Gerald Aichinger, Mary Kate Hart, Hartmut J Ehrlich

Lancet· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody to the E3 glycoprotein protects mice against lethal venezuelan equine encephalitis virus infection.
Michael D Parker, Marilyn J Buckley, Vanessa R Melanson, Pamela J Glass, David Norwood, Mary Kate Hart

J Virol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V).
Patricia Fellows, Jeffrey Adamovicz, Justin Hartings, Robert Sherwood, William Mega, Mary Kate Hart

Vaccine· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.
Shannon S Martin, Russell R Bakken, Cathleen M Lind, Patricia Garcia, Erin Jenkins, Mary Kate Hart

Vaccine· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB.
Shannon S Martin, Russell R Bakken, Cathleen M Lind, Patricia Garcia, Erin Jenkins, Mary Kate Hart

Vaccine· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telemetric analysis to detect febrile responses in mice following vaccination with a live-attenuated virus vaccine.
Shannon S Martin, Russell R Bakken, Cathleen M Lind, Douglas S Reed, Jessica L Price, Mary Kate Hart

Vaccine· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain.
Jeffrey E Lee, Ana Kuehne, Dafna M Abelson, Marnie L Fusco, Mary Kate Hart

J Mol Biol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Danher Wang, Nicholas U Raja, Charles M Trubey, Laure Y Juompan, Min Luo, Mary Kate Hart

J Virol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins.
Gene G Olinger, Michael A Bailey, John M Dye, Russell Bakken, Ana Kuehne, Mary Kate Hart

J Virol· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection.
Kelly L Warfield, Gene Olinger, Emily M Deal, Dana L Swenson, Michael Bailey, Mary Kate Hart

J Immunol· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus.
Jenny Riemenschneider, Aura Garrison, Joan Geisbert, Peter Jahrling, Michael Hevey, Mary Kate Hart

Vaccine· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccine research efforts for filoviruses.
Mary Kate Hart

Int J Parasitol· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of mycoplasma contamination in the anthrax vaccine.
Mary Kate Hart, Richard A Del Giudice, George W Korch

Emerg Infect Dis· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis